Evidence map›Paper›PMID 38578636›Full record

ArticleJAMA network open2024

Access to Specialty Care for Commercially Insured Youths With Type 1 and Type 2 Diabetes.

Christine A March, Amy R Byerly, Linda Siminerio, Elizabeth Miller, Scott Rothenberger, Ingrid Libman

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Pharmacoequity measurement framework: A tool to reduce health disparities.Journal of managed care & specialty pharmacy · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Christine A MarchDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Amy R ByerlyDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Linda SiminerioDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Elizabeth MillerDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Scott RothenbergerDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Ingrid LibmanDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
University of Pittsburgh · USChildren's Hospital of Pittsburgh · US

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
Institutional Career Development CoreKL2TR001856 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RAY, KRISTIN N, RUBIO, DORIS M · 2016 to 2025
$13.8M
School-Partnered Collaborative Care (SPACE) for Pediatric Type 1 DiabetesK23DK135800 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Christine March · 2023 to 2026
$753k
NCATS NIH HHS KL2 TR001856NCATS NIH HHS UL1 TR001857NIDDK NIH HHS K23 DK135800
6 · The paper itself

Abstract

Importance: Youths with type 2 diabetes are at higher risk for complications compared with peers with type 1 diabetes, though few studies have evaluated differences in access to specialty care. Objective: To compare claims with diabetes specialists for youths with type 1 vs type 2 diabetes and the association between specialist claims with multidisciplinary and acute care utilization. Design, Setting, and Participants: This cross-sectional study used Optum Clinformatics Data Mart commercial claims. Individuals included in the study were youths younger than 19 years with type 1 or 2 diabetes as determined by a validated algorithm and prescription claims. Data were collected for youths with at least 80% enrollment in a commercial health plan from December 1, 2018, to December 31, 2019. Statistical analysis was performed from September 2022 to January 2024. Main Outcomes and Measures: The primary outcome was the number of ambulatory claims from an endocrine and/or diabetes physician or advanced practice clinician associated with a diabetes diagnosis code; secondary outcomes included multidisciplinary and acute care claims. Results: Claims were analyzed for 4772 youths (mean [SD] age, 13.6 [3.7] years; 4300 [90.1%] type 1 diabetes; 472 [9.9%] type 2 diabetes; 2465 [51.7%] male; 128 [2.7%] Asian, 303 [6.4] Black or African American, 429 [9.0%] Hispanic or Latino, 3366 [70.5%] non-Hispanic White, and 546 [11.4%] unknown race and ethnicity). Specialist claims were lower in type 2 compared with type 1 diabetes (incidence rate ratio [IRR], 0.61 [95% CI, 0.52-0.72]; P < .001) in propensity score-weighted analyses. The presence of a comorbidity was associated with increased specialist claims for type 1 diabetes (IRR, 1.07 [95% CI, 1.03-1.10]) and decreased claims for type 2 diabetes (IRR, 0.77 [95% CI, 0.67-0.87]). Pooling diagnosis groups and adjusted for covariates, each additional specialist claim was associated with increased odds of a claim with a diabetes care and education specialist (odds ratio [OR], 1.31 [95% CI, 1.25-1.36]), dietitian (OR, 1.14 [95% CI, 1.09-1.19]), and behavioral health clinician (OR, 1.16 [95% CI, 1.12-1.20]). For acute care claims, each additional specialist claim was associated with increased odds of admission (OR, 1.17 [95% CI, 1.11-1.24]) but not for emergency claims (OR, 1.03 [95% CI, 0.98-1.82]). Conclusions and Relevance: This cross-sectional study found that youths with type 2 diabetes were significantly less likely to have specialist claims despite insurance coverage, indicating other barriers to care, which may include medical complexity. Access to diabetes specialists influences engagement with multidisciplinary services. The association between increasing ambulatory clinician services and admissions suggests high utilization by a subgroup of patients at greater risk for poor outcomes.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2AdolescentCross-Sectional StudiesEthnicityFemaleHumansMaleRetrospective Studies

Identifiers

PMID38578636
PMCPMC10998152
OpenAlexW4393995302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.